首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 再生醫學細胞療法基因療法

歐洲細胞和基因治療製造服務市場預測至 2030 年 - 區域分析 - 按類型、適應症（癌症、骨科等）、應用（臨床製造和商業製造）和最終用戶

市場調查報告書

商品編碼

1452624

歐洲細胞和基因治療製造服務市場預測至 2030 年 - 區域分析 - 按類型、適應症（癌症、骨科等）、應用（臨床製造和商業製造）和最終用戶

Europe Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 - Regional Analysis - by Type, Indication (Cancer, Orthopedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 119 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

歐洲細胞和基因治療製造服務市場預計將從2022年的18.7977億美元成長到2030年的65.6385億美元。預計2022年至2030年CAGR為16.9%。

公司的策略性舉措推動歐洲細胞和基因治療製造服務市場

在細胞和基因治療製造服務市場中營運的公司專注於策略發展，例如合作、擴張、協議、夥伴關係和新產品發布，這有助於他們提高銷售、擴大地理覆蓋範圍並增強迎合市場需求的能力。比現有的客戶群更大。以下提到了細胞和基因治療製造服務市場的一些值得注意的發展。

2023 年 5 月，Lonza 推出了 TheraPEAK T-VIVO 細胞培養基，採用新型化學成分確定的配方，旨在最佳化和簡化 CAR T 細胞的製造。與其他無血清培養基不同，TheraPEAK T-VIVO 細胞培養基無需添加人類血清或其成分即可表現出高性能。

2022年10月，輝瑞公司完成了對Biohaven Pharmaceutical Holding Company Ltd.的收購，Biohaven Pharmaceutical Holding Company Ltd.是NURTEC ODT（rimegepant）的製造商，NURTEC ODT（rimegepant）是一種創新的偏頭痛療法，被核准用於成人發作性偏頭痛的急性治療和預防。

2022 年 3 月，Cellevolve Bio 與西雅圖兒童治療公司合作，開發和商業化用於兒童癌症的新型多重 CAR。根據此次合作，合作夥伴將專注於 BrainChild 研究項目，該項目由五種多重 CAR 組成，用於治療兒童中樞神經系統 (CNS) 惡性腫瘤。透過合作，他們將利用西雅圖兒童治療工廠設施對新 CAR 進行早期臨床 GMP 研究。

因此，這些策略措施為細胞和基因治療製造服務市場創造了巨大的成長機會。

歐洲細胞與基因治療製造服務市場概述

歐洲細胞和基因治療製造服務市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。該地區將在未來幾年佔據重要的市場佔有率。由於產能建設投資、政府的大力支持和對該地區的參與等因素，歐洲、美國和歐洲的細胞和基因治療製造服務市場預計將在預測期內顯著成長。此外，頂級競爭者的出現將進一步促進 2022-2030 年預測期內區域市場的成長。

德國擁有強大的製藥業，尤其注重研發。該國擁有 660 家生技公司，僱用 5 萬名員工。其中，660家公司專注於CGT。根據 NecstGen 的報告，2021 年正在進行超過 29 項評估 CAR 修飾免疫細胞的活躍臨床試驗，其中大部分生產涉及 CAR-T 細胞。此外，德國迄今已進行了超過50項基因治療臨床研究。德國 CGT 公司的創新努力主要集中在地方或國家層面，因為它們缺乏國際影響力。

英國是世界上先進療法的研究、開發、製造、臨床採用和報銷的最佳生態系統之一。目前，英國正在進行超過 85 項臨床試驗，70 家 CGT 公司正在開發潛在的治療方法。 2018年，英國國家醫療服務體系（NHS）宣佈為癌症患者提供CAR-T細胞治療，這是首次為這些患者提供這種療法。

Catapult 是另一家為英國 CGT 生態系統做出重大貢獻的頂級公司；它是該國開發製造程序的前五名公司之一。該公司正在開發更智慧的自動化 CGT 製造流程，能夠以最少的干涉自動適應不斷變化的環境和流程要求。因此，這些公司在提高生產力和降低最終成本方面所做的努力是推動英國歐洲細胞和基因治療製造服務市場成長的主要因素。此外，由於對研究的持續和有針對性的投資，英國在歐洲細胞和基因治療製造服務市場中佔據強勢地位。

歐洲細胞和基因治療製造服務市場收入及 2030 年預測（百萬美元）

歐洲細胞和基因治療製造服務市場細分

歐洲細胞和基因治療製造服務市場分為類型、適應症、應用、最終用戶和國家。

根據類型，歐洲細胞和基因治療製造服務市場分為細胞治療和基因治療。 2022年，細胞治療領域在歐洲細胞和基因治療製造服務市場中佔據更大佔有率。細胞治療部分進一步分為自體細胞治療和同種異體細胞治療。基因治療部分進一步細分為病毒載體和非病毒載體。

根據跡象，歐洲細胞和基因治療製造服務市場分為癌症、骨科等。 2022年，癌症領域在歐洲細胞和基因治療製造服務市場中佔據最大佔有率。

根據應用，歐洲細胞和基因治療製造服務市場分為臨床製造和商業製造。 2022年，商業製造領域在歐洲細胞和基因治療製造服務市場中佔據最大佔有率。

根據最終用戶，歐洲細胞和基因治療製造服務市場分為製藥和生物技術公司和合約研究組織（CRO）。 2022年，製藥和生物技術公司部門在歐洲細胞和基因治療製造服務市場中佔據更大佔有率。

根據國家/地區，歐洲細胞和基因治療製造服務市場分為英國、法國、德國、西班牙、義大利和歐洲其他地區。 2022年，英國在歐洲細胞和基因治療製造服務市場中佔據最大佔有率。

Catalent Inc、Charles River Laboratories International Inc、FUJIFILM Holdings Corp、Lonza Group AG、Merck KgaA、Nikon Corp、Oxford BioMedica Plc、Takara Bio Inc、Thermo Fisher Scientific Inc 和 WuXi AppTec Co Ltd 是該領域的一些領先公司。歐洲細胞細胞細胞和基因治療製造服務市場。

Companies operating in the cell and gene therapy manufacturing services market focus on strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. A few of the noteworthy developments in the cell and gene therapy manufacturing services market are mentioned below.

In May 2023, Lonza launched the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation devised to optimize and streamline CAR T-cell manufacturing. The TheraPEAK T-VIVO Cell Culture Medium can exhibit a high performance without the need to add human serum or its components, unlike other serum-free media.

In October 2022, Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd., the manufacturer of NURTEC ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.

In March 2022, Cellevolve Bio partnered with Seattle Children's Therapeutics to develop and commercialize new multiplex CARs for paediatric cancers. Under the collaboration, the partners will focus on the BrainChild research program, a suite of five multiplex CARs, to treat pediatric central nervous system (CNS) malignancies. In partnership, they would leverage the Seattle Children's Cure Factory facility to conduct early clinical GMP research on new CARs.

Thus, these strategic initiatives create significant growth opportunities in the cell and gene therapy manufacturing services market.

Europe Cell and Gene Therapy Manufacturing Services Market Overview

The Europe cell and gene therapy manufacturing services market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region will hold a significant market share in the coming years. The European US and Europe cell and gene therapy manufacturing services market is expected to witness significant growth during the forecast period due to factors such as the investment for setup of production capacity, high government support and involvement in the region. Also, presence of top competitive players will further enhance the regional market growth during the forecast period 2022-2030.

Germany has a strong pharmaceutical industry with a notable focus on R&D. The country has 660 biotechnology companies that employ 50,000 employees. Among these, 660 companies are focused on CGT. As per the NecstGen report, more than 29 active clinical trials evaluating CAR-modified immune cells were ongoing in 2021, and the majority of the production involved CAR-T cells. Also, over 50 clinical studies have been conducted in gene therapy in Germany so far. The innovation efforts of German CGT companies are majorly focused on the local or country level, as they lack international presence.

The UK is one of the world's best ecosystems for research, development, manufacturing, clinical adoption, and reimbursement of advanced therapeutics. Currently, over 85 clinical trials are ongoing in the UK, and 70 CGTs companies are operating for the development of potentially curative therapies. In 2018, National Health Services (NHS) England announced the availability of CAR-T cell treatment for cancer patients, which was the first time when this therapy was made available to these patients.

Catapult is another top company that has been contributing significantly to the CGT ecosystem in the UK; it stands as one of the top five companies in developing manufacturing processes in the country. The company is developing smarter automated CGT manufacturing processes that can automatically adapt to changing environments and process requirements with minimal intervention. Therefore, efforts made by these companies for enhancing productivity and reducing the final costs are the major factors driving the growth of the Europe cell and gene therapy manufacturing services market in the UK. Moreover, the UK holds a strong position in the Europe cell and gene therapy manufacturing services market in Europe owing to sustained and targeted investment in research.

Europe Cell and Gene Therapy Manufacturing Services Market Revenue and Forecast to 2030 (US$ Million)

Europe Cell and Gene Therapy Manufacturing Services Market Segmentation

The Europe cell and gene therapy manufacturing services market is segmented into type, indication, application, end user, and country.

Based on type, the Europe cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. In 2022, the cell therapy segment registered a larger share in the Europe cell and gene therapy manufacturing services market. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.

Based on indication, the Europe cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. In 2022, the cancer segment registered the largest share in the Europe cell and gene therapy manufacturing services market.

Based on application, the Europe cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. In 2022, the commercial manufacturing segment registered the largest share in the Europe cell and gene therapy manufacturing services market.

Based on end user, the Europe cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). In 2022, the pharmaceutical and biotechnology companies segment registered a larger share in the Europe cell and gene therapy manufacturing services market.

Based on country, the Europe cell and gene therapy manufacturing services market is segmented into the UK, France, Germany, Spain, Italy, and the Rest of Europe. In 2022, the UK registered the largest share in the Europe cell and gene therapy manufacturing services market.

Catalent Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Lonza Group AG, Merck KgaA, Nikon Corp, Oxford BioMedica Plc, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd are some of the leading companies operating in the Europe cell and gene therapy manufacturing services market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Cell and Gene Therapy Manufacturing Services Market Landscape

4.1 Overview
4.2 Europe PEST Analysis

5. Europe Cell and Gene Therapy Manufacturing Services Market - Key Industry Dynamics

5.1 Key Market Drivers:
- 5.1.1 Increase in Number of Approval of Cell and Gene Therapies
- 5.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
5.2 Market Restraints
- 5.2.1 High Cost of Cell and Gene Therapy Manufacturing
5.3 Market Opportunities
- 5.3.1 Strategic Initiatives by Companies
5.4 Future Trends
- 5.4.1 Automation of Cell and Gene Therapy Manufacturing Services
5.5 Impact Analysis:

6. Europe Cell and Gene Therapy Manufacturing Services Market - Europe Market Analysis

6.1 Europe Cell and Gene Therapy Market Revenue (US$ Mn), 2022 - 2030

7. Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Type

7.1 Overview
7.2 Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
7.3 Cell Therapy
- 7.3.1 Overview
- 7.3.2 Cell Therapy: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.3.2.1 Autologous
    - 7.3.2.1.1 Overview
    - 7.3.2.1.2 Autologous: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.3.2.2 Allogenic
    - 7.3.2.2.1 Overview
    - 7.3.2.2.2 Allogenic: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Gene Therapy
- 7.4.1 Overview
- 7.4.2 Gene Therapy: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.4.2.1 Viral Vector
    - 7.4.2.1.1 Overview
    - 7.4.2.1.2 Viral Vector: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.4.2.2 Non-Viral Vector
    - 7.4.2.2.1 Overview
    - 7.4.2.2.2 Non-Viral Vector: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Cell and Gene Therapy Manufacturing Services Market Analysis and Forecasts to 2030 - by Indication

8.1 Overview
8.2 Europe Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
8.3 Cancer
- 8.3.1 Overview
- 8.3.2 Cancer: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Orthopedics
- 8.4.1 Overview
- 8.4.2 Orthopedics: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Application

9.1 Overview
9.2 Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
9.4 Clinical Manufacturing
- 9.4.1 Overview
- 9.4.2 Clinical Manufacturing: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Commercial Manufacturing
- 9.5.1 Overview
- 9.5.2 Commercial Manufacturing: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by End User

10.1 Overview
10.2 Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
10.4 Pharmaceutical and Biotechnology Companies
- 10.4.1 Overview
- 10.4.2 Pharmaceutical & Biotechnology Companies: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
10.5 Contract Research Organizations (CROs)
- 10.5.1 Overview
- 10.5.2 Contract Research Organizations (CROs): Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - Country Analysis

11.1 Overview
- 11.1.1 Europe: Europe Cell and Gene Therapy Manufacturing Services Market, By Country, 2022 & 2030 (%)
  - 11.1.1.1 Germany: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.1.1.1 Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 11.1.1.1.1.1 Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 11.1.1.1.1.2 Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 11.1.1.1.2 Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 11.1.1.1.3 Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 11.1.1.1.4 Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 11.1.1.2 UK: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.1.2.1 UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 11.1.1.2.1.1 UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 11.1.1.2.1.2 UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 11.1.1.2.2 UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 11.1.1.2.3 UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 11.1.1.2.4 UK: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 11.1.1.3 France: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.1.3.1 France: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 11.1.1.3.1.1 France: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 11.1.1.3.1.2 France: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 11.1.1.3.2 France: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 11.1.1.3.3 France: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 11.1.1.3.4 France: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 11.1.1.4 Italy: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.1.4.1 Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 11.1.1.4.1.1 Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 11.1.1.4.1.2 Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 11.1.1.4.2 Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 11.1.1.4.3 Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 11.1.1.4.4 Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 11.1.1.5 Spain: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.1.5.1 Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 11.1.1.5.1.1 Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 11.1.1.5.1.2 Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 11.1.1.5.2 Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 11.1.1.5.3 Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 11.1.1.5.4 Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 11.1.1.6 Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.1.6.1 Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 11.1.1.6.1.1 Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 11.1.1.6.1.2 Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 11.1.1.6.2 Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 11.1.1.6.3 Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 11.1.1.6.4 Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)

12. Europe Cell and Gene Therapy Manufacturing Services Market - Industry Landscape

12.1 Overview
12.2 Growth Strategies in Europe Cell and Gene Therapy Manufacturing Services Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Thermo Fisher Scientific Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Merck KGaA
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Charles River Laboratories International Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Lonza Group AG
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 WuXi AppTec Co Ltd?
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Catalent Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Takara Bio Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Nikon Corp
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 FUJIFILM Holdings Corp
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Oxford BioMedica Plc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

簡介目錄圖表

List Of Tables

Table 1. Europe Cell and Gene Therapy Market Segmentation
Table 2. Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 3. Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 4. Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 5. Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 6. Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 7. Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 8. UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 9. UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 10. UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 11. UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 12. UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 13. UK: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 14. France: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 15. France: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 16. France: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 17. France: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 18. France: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 19. France: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 20. Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 21. Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 22. Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 23. Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 24. Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 25. Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 26. Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 27. Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 28. Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 29. Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 30. Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 31. Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 32. Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 33. Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 34. Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 35. Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 36. Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 37. Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 38. Recent Organic Growth Strategies in Europe Cell and Gene Therapy Manufacturing Services Market
Table 39. Recent Inorganic Growth Strategies in the Europe Cell and Gene Therapy Manufacturing Services Market

List Of Figures

Figure 1. Europe Cell and Gene Therapy Market Segmentation, By Country
Figure 2. Europe PEST Analysis
Figure 3. Europe Cell and Gene Therapy Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Europe Cell and Gene Therapy Market Revenue (US$ Mn), 2022 - 2030
Figure 6. Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
Figure 7. Cell Therapy: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Autologous: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Allogenic: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Gene Therapy: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Viral Vector: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Non-Viral Vector: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Europe Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
Figure 14. Cancer: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Orthopedics: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Others: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
Figure 18. Clinical Manufacturing: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Commercial Manufacturing: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
Figure 21. Pharmaceutical & Biotechnology Companies: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 22. Contract Research Organizations (CROs): Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Europe: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
Figure 24. Europe: Europe Cell and Gene Therapy Manufacturing Services Market, By Country, 2022 & 2030 (%)
Figure 25. Germany: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 26. UK: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 27. France: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Italy: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. Spain: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 30. Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 31. Growth Strategies in Europe Cell and Gene Therapy Manufacturing Services Market